Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)

Introduction: Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by a biallelic mutation of the SMN1 gene, located on the long arm of chromosome 5, and predominantly affects the motor neurons of the anterior horn of the spinal cord, causing progressive muscle weakness and atrophy. T...

Descripción completa

Detalles Bibliográficos
Autores: Pitarch Castellano, I, Cabrera-Serrano, Macarena, Calvo Medina, Rocío, Cattinari, Maria Grazia, Espinosa Garcia, S., Fernandez-Ramos, J. A., Garcia Campos, O., Gomez-andres, D., Grimalt Calatayud, M. A., Gutierrez Martinez, A. J., Ibanez Albert, E., Kapetanovic Garcia, S., Madruga-Garrido, M., Martinez-Moreno, M., Medina Cantillo, J., Melian Suarez, A., I, Moreno Escribano, A., Munell, F., Nascimento Osorio, A., Pascual-Pascual, Samuel I., Povedano, M., Santana Casiano, I. M., Vazquez-Costa, J. F.
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/19527
Acceso en línea:https://hdl.handle.net/20.500.13003/19527
Access Level:acceso abierto
Palabra clave:Child
Muscular Atrophy, Spinal
Infant, Newborn
Spain
Neurodegenerative Diseases
Delphi Technique
Humans
Consensus
Consenso
Humanos
Técnica Delfos
Enfermedades Neurodegenerativas
Recién Nacido
Atrofia Muscular Espinal
Niño
España
Spinal muscular atrophy (SMA)
Treatment
Delphi
Neuromuscular
id ES_fdc5002dfd4404fff8c6d31eff123c65
oai_identifier_str oai:docusalut.com:20.500.13003/19527
network_acronym_str ES
network_name_str España
repository_id_str
spelling Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)Pitarch Castellano, ICabrera-Serrano, MacarenaCalvo Medina, RocíoCattinari, Maria GraziaEspinosa Garcia, S.Fernandez-Ramos, J. A.Garcia Campos, O.Gomez-andres, D.Grimalt Calatayud, M. A.Gutierrez Martinez, A. J.Ibanez Albert, E.Kapetanovic Garcia, S.Madruga-Garrido, M.Martinez-Moreno, M.Medina Cantillo, J.Melian Suarez, A., IMoreno Escribano, A.Munell, F.Nascimento Osorio, A.Pascual-Pascual, Samuel I.Povedano, M.Santana Casiano, I. M.Vazquez-Costa, J. F.ChildMuscular Atrophy, SpinalInfant, NewbornSpainNeurodegenerative DiseasesDelphi TechniqueHumansConsensusConsensoHumanosTécnica DelfosEnfermedades NeurodegenerativasRecién NacidoAtrofia Muscular EspinalNiñoEspañaSpinal muscular atrophy (SMA)TreatmentDelphiNeuromuscularIntroduction: Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by a biallelic mutation of the SMN1 gene, located on the long arm of chromosome 5, and predominantly affects the motor neurons of the anterior horn of the spinal cord, causing progressive muscle weakness and atrophy. The development of disease-modifying treatments is significantly changing the natural history of SMA, but uncertainty remains about which patients can benefit from these treatments and how that benefit should be measured.Methodology: A group of experts specialised in neurology, neuropediatrics, and rehabilitation and representatives of the Spanish association of patients with SMA followed the Delphi method to reach a consensus on 5 issues related to the use of these new treatments: general aspects, treatment objectives, outcome assessment tools, requirements of the treating centres, and regulation of their use. Consensus was considered to be achieved when a response received at least 80% of votes.Results: Treatment protocols are useful for regulating the use of high-impact medications and should guide treatment, but should be updated regularly to take into account the most recent evidence available, and their implementation should be assessed on an individual basis. Age, baseline functional status, and, in the case of children, the type of SMA and the number of copies of SMN2 are characteristics that should be considered when establishing therapeutic objectives, assessment tools, and the use of such treatments. The cost-effectiveness of these treatments in paediatric patients is mainly influenced by early treatment onset; therefore, the implementation of neonatal screening is recommended.Conclusions: The RET-AME consensus recommendations provide a frame of reference for the appropriate use of disease-modifying treatments in patients with SMA. (c) 2021 Sociedad Espanola de Neurologi acute accent a. Published by Elsevier Espana, S.L.U. This is an open access research article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).Elsevier Espana Slu20222022-04-0120222022-04-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/19527reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/195272026-06-22T12:44:07Z
dc.title.none.fl_str_mv Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)
title Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)
spellingShingle Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)
Pitarch Castellano, I
Child
Muscular Atrophy, Spinal
Infant, Newborn
Spain
Neurodegenerative Diseases
Delphi Technique
Humans
Consensus
Consenso
Humanos
Técnica Delfos
Enfermedades Neurodegenerativas
Recién Nacido
Atrofia Muscular Espinal
Niño
España
Spinal muscular atrophy (SMA)
Treatment
Delphi
Neuromuscular
title_short Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)
title_full Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)
title_fullStr Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)
title_full_unstemmed Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)
title_sort Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)
dc.creator.none.fl_str_mv Pitarch Castellano, I
Cabrera-Serrano, Macarena
Calvo Medina, Rocío
Cattinari, Maria Grazia
Espinosa Garcia, S.
Fernandez-Ramos, J. A.
Garcia Campos, O.
Gomez-andres, D.
Grimalt Calatayud, M. A.
Gutierrez Martinez, A. J.
Ibanez Albert, E.
Kapetanovic Garcia, S.
Madruga-Garrido, M.
Martinez-Moreno, M.
Medina Cantillo, J.
Melian Suarez, A., I
Moreno Escribano, A.
Munell, F.
Nascimento Osorio, A.
Pascual-Pascual, Samuel I.
Povedano, M.
Santana Casiano, I. M.
Vazquez-Costa, J. F.
author Pitarch Castellano, I
author_facet Pitarch Castellano, I
Cabrera-Serrano, Macarena
Calvo Medina, Rocío
Cattinari, Maria Grazia
Espinosa Garcia, S.
Fernandez-Ramos, J. A.
Garcia Campos, O.
Gomez-andres, D.
Grimalt Calatayud, M. A.
Gutierrez Martinez, A. J.
Ibanez Albert, E.
Kapetanovic Garcia, S.
Madruga-Garrido, M.
Martinez-Moreno, M.
Medina Cantillo, J.
Melian Suarez, A., I
Moreno Escribano, A.
Munell, F.
Nascimento Osorio, A.
Pascual-Pascual, Samuel I.
Povedano, M.
Santana Casiano, I. M.
Vazquez-Costa, J. F.
author_role author
author2 Cabrera-Serrano, Macarena
Calvo Medina, Rocío
Cattinari, Maria Grazia
Espinosa Garcia, S.
Fernandez-Ramos, J. A.
Garcia Campos, O.
Gomez-andres, D.
Grimalt Calatayud, M. A.
Gutierrez Martinez, A. J.
Ibanez Albert, E.
Kapetanovic Garcia, S.
Madruga-Garrido, M.
Martinez-Moreno, M.
Medina Cantillo, J.
Melian Suarez, A., I
Moreno Escribano, A.
Munell, F.
Nascimento Osorio, A.
Pascual-Pascual, Samuel I.
Povedano, M.
Santana Casiano, I. M.
Vazquez-Costa, J. F.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Child
Muscular Atrophy, Spinal
Infant, Newborn
Spain
Neurodegenerative Diseases
Delphi Technique
Humans
Consensus
Consenso
Humanos
Técnica Delfos
Enfermedades Neurodegenerativas
Recién Nacido
Atrofia Muscular Espinal
Niño
España
Spinal muscular atrophy (SMA)
Treatment
Delphi
Neuromuscular
topic Child
Muscular Atrophy, Spinal
Infant, Newborn
Spain
Neurodegenerative Diseases
Delphi Technique
Humans
Consensus
Consenso
Humanos
Técnica Delfos
Enfermedades Neurodegenerativas
Recién Nacido
Atrofia Muscular Espinal
Niño
España
Spinal muscular atrophy (SMA)
Treatment
Delphi
Neuromuscular
description Introduction: Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by a biallelic mutation of the SMN1 gene, located on the long arm of chromosome 5, and predominantly affects the motor neurons of the anterior horn of the spinal cord, causing progressive muscle weakness and atrophy. The development of disease-modifying treatments is significantly changing the natural history of SMA, but uncertainty remains about which patients can benefit from these treatments and how that benefit should be measured.Methodology: A group of experts specialised in neurology, neuropediatrics, and rehabilitation and representatives of the Spanish association of patients with SMA followed the Delphi method to reach a consensus on 5 issues related to the use of these new treatments: general aspects, treatment objectives, outcome assessment tools, requirements of the treating centres, and regulation of their use. Consensus was considered to be achieved when a response received at least 80% of votes.Results: Treatment protocols are useful for regulating the use of high-impact medications and should guide treatment, but should be updated regularly to take into account the most recent evidence available, and their implementation should be assessed on an individual basis. Age, baseline functional status, and, in the case of children, the type of SMA and the number of copies of SMN2 are characteristics that should be considered when establishing therapeutic objectives, assessment tools, and the use of such treatments. The cost-effectiveness of these treatments in paediatric patients is mainly influenced by early treatment onset; therefore, the implementation of neonatal screening is recommended.Conclusions: The RET-AME consensus recommendations provide a frame of reference for the appropriate use of disease-modifying treatments in patients with SMA. (c) 2021 Sociedad Espanola de Neurologi acute accent a. Published by Elsevier Espana, S.L.U. This is an open access research article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-04-01
2022
2022-04-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.13003/19527
url https://hdl.handle.net/20.500.13003/19527
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier Espana Slu
publisher.none.fl_str_mv Elsevier Espana Slu
dc.source.none.fl_str_mv reponame:Docusalut
instname:Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
reponame_str Docusalut
collection Docusalut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425597242933248
score 15,81155